Survivin has been regarded as an ideal target for tumor therapy due to its overexpression in most human cancers but not in most normal tissues; it can inhibit the activation of caspase‐7 and caspase‐3 by binding to caspase‐9 to inhibit the apoptosis process.39 Here, BIRC5 is linked to neoplasm.